Recro Pharma Inc. (REPH)
Company Description
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally.
It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services.
The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008.
Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Country | United States |
IPO Date | Mar 7, 2014 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 185 |
CEO | Geraldine Henwood |
Contact Details
Address: 490 Lapp Rd Malvern, Pennsylvania United States | |
Website | https://www.recrocdmo.com |
Stock Details
Ticker Symbol | REPH |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001588972 |
CUSIP Number | 75629F109 |
ISIN Number | US75629F1093 |
Employer ID | 26-1523233 |
SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 18, 2024 | 15-12G | Filing |
Apr 09, 2024 | SC 13D/A | [Amend] Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |
Apr 08, 2024 | 4 | Filing |